The latest research, treatments for biliary diseases presented at The Liver Meeting
Click Here to Manage Email Alerts
Didn’t make it to the meeting? Here’s a collection of Healio-curated highlights, including expert insight on the latest research and treatments for biliary diseases, including primary biliary cholangitis, progressive familial cholestasis and more.
VIDEO: Primary biliary cholangitis treatments poised to be clinically ‘impactful’
Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE trial, which were presented at the meeting.
Boyer, emeritus director of the Yale Liver Center, told Healio that these phase 3 trials were “probably the most impactful” studies in biliary diseases presented at the meeting. Watch here.
VIDEO: Treatment with Livmarli yields ‘broad base effects’ across range of PFIC types
In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.
“MARCH was the largest phase 3 study ever to be conducted in this rare disease of PFIC, which encompasses groups of different genetic mutations that really affect bile acid composition and transport,” Vig, head of research and development for Mirum Pharmaceuticals Inc., said. “As a result, these children have significantly elevated bile acids which affect liver health.” Watch here.
VIDEO: Interim INTEGRIS-PSC trial results ‘promising’ in primary sclerosing cholangitis
Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo. Watch here.
Elafibranor achieves response, improves pruritus symptoms in primary biliary cholangitis
After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented. Read more.
VIDEO: Preclinical research investigates role of Claudin-1 in cholangiocarcinoma
Healio spoke with James L. Boyer, MD, FACEP, about research assessing the role of Claudin-1 in cholangiocarcinoma, which was presented at the meeting. Watch here.
More from The Liver Meeting:
Collapse
Healio Coverage
Click Here to Manage Email Alerts